Gabrielle Scher

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 10

Top Topics

Candida Albicans

Monoclonal Antibody

Top Venues

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Colleen Furey, Gabrielle Scher, Naiqing Ye, Lisa Kercher, Jennifer DeBeauchamp, Jeri Carol Crumpton, Trushar Jeevan, Christopher Patton, John Franks, Adam Rubrum, Mohamad Gabriel Alameh, Steven H Y Fan, Anthony T Phan, Christopher A Hunter, Richard John Webby, Drew Weissman, Scott E Hensley
Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus. Nature communications 15 (1) (2024)
Colleen Furey, Gabrielle Scher, Naiqing Ye, Lisa Kercher, Jennifer DeBeauchamp, Jeri Carol Crumpton, Trushar Jeevan, Christopher Patton, John Franks, Adam Rubrum, Mohamad Gabriel Alameh, Steven H Y Fan, Anthony T Phan, Christopher A Hunter, Richard John Webby, Drew Weissman, Scott E Hensley
Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus. Nature communications 15 (1) (2024)
Colleen Furey, Gabrielle Scher, Naiqing Ye, Lisa Kercher, Jennifer DeBeauchamp, Jeri Carol Crumpton, Trushar Jeevan, Christopher Patton, John Franks, Adam Rubrum, Mohamad Gabriel Alameh, Steven H Y Fan, Anthony T Phan, Christopher A Hunter, Richard John Webby, Drew Weissman, Scott E Hensley
Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus. Nature communications 15 (1) (2024)
Colleen Furey, Gabrielle Scher, Naiqing Ye, Lisa Kercher, Jennifer DeBeauchamp, Jeri Carol Crumpton, Trushar Jeevan, Christopher Patton, John Franks, Adam Rubrum, Mohamad Gabriel Alameh, Steven H Y Fan, Anthony T Phan, Christopher A Hunter, Richard John Webby, Drew Weissman, Scott E Hensley
Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus. Nature communications 15 (1) (2024)
Gabrielle Scher, Catherine Yankowski, Drishya Kurup, Nicole M Josleyn, Eric R Wilkinson, Jay Wells, Jesse Steffens, Ginger Lynn, Sean Vantongeren, Xiankun Zeng, Nancy Twenhafel, Kathleen A Cashman, Matthias J Schnell
Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease. NPJ vaccines 9 (1) (2024)
Gabrielle Scher, Catherine Yankowski, Drishya Kurup, Nicole M Josleyn, Eric R Wilkinson, Jay Wells, Jesse Steffens, Ginger Lynn, Sean Vantongeren, Xiankun Zeng, Nancy Twenhafel, Kathleen A Cashman, Matthias J Schnell
Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease. NPJ vaccines 9 (1) (2024)
Gabrielle Scher, Catherine Yankowski, Drishya Kurup, Nicole M Josleyn, Eric R Wilkinson, Jay Wells, Jesse Steffens, Ginger Lynn, Sean Vantongeren, Xiankun Zeng, Nancy Twenhafel, Kathleen A Cashman, Matthias J Schnell
Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease. NPJ vaccines 9 (1) (2024)
Gabrielle Scher, Dennis A Bente, Megan C Mears, Maria N B Cajimat, Matthias J Schnell
GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus. NPJ vaccines 8 (1) (2023)
Gabrielle Scher, Dennis A Bente, Megan C Mears, Maria N B Cajimat, Matthias J Schnell
GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus. NPJ vaccines 8 (1) (2023)
Gabrielle Scher, Dennis A Bente, Megan C Mears, Maria N B Cajimat, Matthias J Schnell
GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus. NPJ vaccines 8 (1) (2023)